<div id="readability-page-1"><p>Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $15.40 and last traded at $15.2110, with a volume of 168397 shares trading hands. The stock had previously closed at $14.22.</p><h2>Analyst Ratings Changes</h2><p>A number of brokerages have commented on GLUE. Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of Monte Rosa Therapeutics in a report on Friday, October 31st. Wells Fargo &amp; Company boosted their price target on Monte Rosa Therapeutics from $10.00 to $13.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Friday, November 7th. Two analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, the company  has an average rating of &#34;Hold&#34; and an average target price of $16.33.</p><p><b>Check Out Our Latest Analysis on GLUE</b></p><h2>Monte Rosa Therapeutics Price Performance</h2><p>The firm has a market cap of $1.01 billion, a P/E ratio of 48.58 and a beta of 1.61. The firm's 50-day moving average price is $10.27 and its 200 day moving average price is $6.69. </p><p>Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.06. The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $7.37 million. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%. Analysts forecast that  Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current year. </p><h2>Institutional Investors Weigh In On Monte Rosa Therapeutics</h2><p>A number of hedge funds have recently added to or reduced their stakes in the stock. Vestal Point Capital LP bought a new position in  Monte Rosa Therapeutics in the 3rd quarter worth approximately $5,928,000.  Scientech Research LLC acquired a new stake in shares of  Monte Rosa Therapeutics during the third quarter worth $120,000.  Prelude Capital Management LLC acquired a new position in shares of  Monte Rosa Therapeutics in the third quarter worth about $76,000.  Millennium Management LLC raised its position in  Monte Rosa Therapeutics by 588.4% during the third quarter. Millennium Management LLC now owns 444,939 shares of the company's stock valued at $3,297,000 after buying an additional 380,308 shares during the period.  Finally, Brevan Howard Capital Management LP increased its stake in  Monte Rosa Therapeutics by 31.2% in the 3rd quarter. Brevan Howard Capital Management LP now owns 46,912 shares of the company's stock valued at $348,000 after buying an additional 11,165 shares during the period. 79.96% of the stock is currently owned by institutional investors. </p><h2>About Monte Rosa Therapeutics</h2> (Get Free Report)<p>Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.</p><h2>Read More</h2><ul><li>Five stocks we like better than Monte Rosa Therapeutics</li><li>What is the MACD Indicator and How to Use it in Your Trading</li><li>Why Costco Stock May Struggle Even as Its Business Thrives</li><li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li><li>Broadcom’s Best Catalyst Yet Might Be Hiding in 2026 Forecasts</li><li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li><li>3 High Growth Revenue Stocks That Wall Street Loves</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Monte Rosa Therapeutics Right Now?</h2><p>Before you consider Monte Rosa Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.</p><p>While Monte Rosa Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GLUE

<p>Monte Rosa Therapeutics (NASDAQ:GLUE) reached a new 52-week high, trading at $15.40. Analysts have mixed ratings: two Buy, one Hold, and one Sell. The average target price is $16.33. The company reported better-than-expected earnings with $12.77 million revenue. Institutional investors hold 79.96% of the stock. Despite the Hold rating, analysts suggest other stocks as better buys.</p>

Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High - Should You Buy?